AMPK activators, such as pioglitazone and PF-06409577, were shown to reduce hepatic fat content and improve splanchnic/peripheral glucose uptake in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) 38, 39. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.